Cita APA

Aguiar, P. N., Haaland, B., Park, W., San Tan, P., del Giglio, A., & de Lima Lopes, G. (2018). Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer. JAMA Oncol.

Chicago Style Citation

Aguiar, Pedro N., Benjamin Haaland, Wungki Park, Pui San Tan, Auro del Giglio, i Gilberto de Lima Lopes. "Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer." JAMA Oncol 2018.

Cita MLA

Aguiar, Pedro N., et al. "Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer." JAMA Oncol 2018.